Samuel J Reich insider trades: SAB Biotherapeutics (SABS) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Samuel reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 29, 2023 | SABS | ↑ Buy | 11,000 | $0.89 | $10K | Direct | Nov 30, 2023 (1d) |
| Oct 14, 2021 | BCYP | ↑ Buy | 1,000 | $10.11 | $10K | Direct | Oct 15, 2021 (1d) |
| Jan 14, 2021 | BCYP | ↑ Buy | 417,200 | $10.00 | $4.2M | Via Big Cypress Holdings LLC | Jan 14, 2021 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Samuel J Reich's insider trades
Samuel J Reich is CEO at SAB Biotherapeutics (SABS). Since Jan 14, 2021, Samuel has reported 3 open-market purchases worth $4.2M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (8 filings), other transactions (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SABS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.